anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-16. Anything still debated is marked as such rather than presented as settled.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
==== Structurally sensitive goods ==== In the case of goods where preservation of structure is required, like food or objects with formerly-living cells, large ice crystals break the cell walls, resulting in increasingly poor texture and loss of nutrients. In this case, rapidly freezing the material to below its eutectic point avoids the formation of large ice crystals. Usually, the freezing temperatures are between −50 °C (−58 °F) and −80 °C (−112 °F).
In some Asian cuisines, fish is traditionally fermented with rice to produce lactic acid that preserves the fish. Examples of these dishes include burong isda of the Philippines; narezushi of Japan; and pla ra of Thailand. The same process is also used for shrimp in the Philippines in the dish known as balao-balao.
The glaucophytes and the red and green algae—clade Archaeplastida (uni- and multicellular) The cryptophytes—clade Cryptista (unicellular) The haptophytes—clade Haptista (unicellular) The dinoflagellates and chromerids in the superphylum Myzozoa, and Pseudoblepharisma in the phylum Ciliophora—clade Alveolata (unicellular) The ochrophytes—clade Stramenopila (uni- and multicellular) The chlorarachniophytes and three species of Paulinella in the phylum Cercozoa—clade Rhizaria (unicellular) The euglenids—clade Excavata (unicellular) Except for the euglenids, which are found within the Excavata, all of these belong to the Diaphoretickes. Archaeplastida and the photosynthetic Paulinella got their plastids, which are surrounded by two membranes, through primary endosymbiosis in two separate events, by engulfing a cyanobacterium. The plastids in all the other groups have either a red or green algal origin, and are referred to as the "red lineages" and the "green lineages". The only known exception is the ciliate Pseudoblepharisma tenue, which in addition to its plastids that originated from green algae also has a purple sulfur bacterium as a symbiont. In dinoflagellates and euglenids the plastids are surrounded by three membranes, and in the remaining lines by four. A nucleomorph, remnants of the original algal nucleus located between the inner and outer membranes of the plastid, is present in the cryptophytes (from a red alga) and chlorarachniophytes (from a green alga).
Anapsida – no fenestrae – cotylosaurs and chelonia (turtles and relatives) Synapsida – one low fenestra – pelycosaurs and therapsids (the 'mammal-like reptiles') Euryapsida – one high fenestra (above the postorbital and squamosal) – protorosaurs (small, early lizard-like reptiles) and the marine sauropterygians and ichthyosaurs, the latter called Parapsida in Osborn's work. Diapsida – two fenestrae – most reptiles, including lizards, snakes, crocodilians, dinosaurs and pterosaurs.
Sources: en.wikipedia.org
== Limitations == The BCA assay is largely incompatible with reducing agents and metal chelators, although trace quantities may be tolerated. The BCA assay also reportedly responds to common membrane lipids and phospholipids.
1962 Waksman Merck postdoc fellowship, USA. 1967 Humboldt assistant professorship stipend at the Max-Planck Institute, Munich, Germany. 1970 visiting professorship at the Weizmann Institute of Science, Rehovot, Israel. 1973 guest professorship in Dallas, Texas, USA. 1978 guest professorship (Japan Society for the Promotion of Science) in Japan. 1982–1986 Full Professor (Ordinarius) in biotechnology at The Federal Institute of technology, ETH Zurich, Switzerland. 1993 honorary visiting professorship in biochemistry at the University of Bath, UK. 1995 honorary visiting professorship in biochemistry at the Université Catholique de Louvain, Louvain-la-Neuve, Belgium. During these stays he collaborated with Nobel Prize winners Lynen, Waksman as well as with Professors Estabrook and Srere, Katchalski-Katzir and Wilchek, Fukui, Chibata, Suzuki, Rees and Creighton respectively.
The liver is a dark reddish brown, wedge-shaped organ with two lobes of unequal size and shape. A human liver normally weighs approximately 1.5 kilograms (3.3 pounds) and has a width of about 15 centimetres (6 inches). There is considerable size variation between individuals, with the standard reference range for men being 970–1,860 grams (2.14–4.10 lb) and for women 600–1,770 g (1.32–3.90 lb). It is both the heaviest internal organ and the largest gland in the human body. It is located in the right upper quadrant of the abdominal cavity, resting just below the diaphragm, to the right of the stomach, and overlying the gallbladder. The liver is connected to two large blood vessels: the hepatic artery and the portal vein. The hepatic artery carries oxygen-rich blood from the aorta via the celiac trunk, whereas the portal vein carries blood rich in digested nutrients from the entire gastrointestinal tract and also from the spleen and pancreas. These blood vessels subdivide into small capillaries known as liver sinusoids, which then lead to hepatic lobules.
mole (mol) A unit (symbol: mol) used to measure the amount of a substance in terms of the absolute number of particles or entities composing the substance. By definition, one mole of any substance contains exactly the Avogadro number (i.e. 6.022×1023) of particles or entities.
EosFP is a photoactivatable green to red fluorescent protein. Its green fluorescence (516 nm) switches to red (581 nm) upon UV irradiation of ~390 nm (violet/blue light) due to a photo-induced modification resulting from a break in the peptide backbone near the chromophore. Eos was first discovered as a tetrameric protein in the stony coral Lobophyllia hemprichii. Like other fluorescent proteins, Eos allows for applications such as the tracking of fusion proteins, multicolour labelling and tracking of cell movement. Several variants of Eos have been engineered for use in specific study systems including mEos2, mEos4 and CaMPARI.
Sources: en.wikipedia.org
=== Depapillation === In some diseases, there can be depapillation of the tongue, where the lingual papillae are lost, leaving a smooth, red and possibly sore area. Examples of depapillating oral conditions include geographic tongue, median rhomboid glossitis and other types of glossitis. The term glossitis, particularly atrophic glossitis is often used synonymously with depapillation. Where the entire dorsal surface of the tongue has lost its papillae, this is sometimes termed "bald tongue". Nutritional deficiencies of iron, folic acid, and B vitamins may cause depapillation of the tongue.
=== Regulation === The level of regulation includes Schedule IV non-narcotic (depressant) (ACSCN 2285) in the United States under the Controlled Substances Act 1970—but along with a few other barbiturates and at least one benzodiazepine, and codeine, dionine, or dihydrocodeine at low concentrations, it also has exempt prescription and had at least one exempt OTC combination drug now more tightly regulated for its ephedrine content. The phenobarbitone/phenobarbital exists in subtherapeutic doses which add up to an effective dose to counter the overstimulation and possible seizures from a deliberate overdose in ephedrine tablets for asthma, which are now regulated at the federal and state level as: a restricted OTC medicine and/or watched precursor, uncontrolled but watched/restricted prescription drug & watched precursor, a Schedule II, III, IV, or V prescription-only controlled substance & watched precursor, or a Schedule V (which also has possible regulations at the county/parish, town, city, or district as well aside from the fact that the pharmacist can also choose not to sell it, and photo ID and signing a register is required) exempt Non-Narcotic restricted/watched OTC medicine.
In 1975 Lagin released Seastones, a quadraphonic album of electronic music (composed between 1970–1974 and constituting a small part of the complete Seastones composition) on Round Records and then United Artists Records. A new, two CD album of Seastones was released on March 8, 2018. This album, not a re-issue, presents most but not all of the composition as originally composed but never released or heard before. For this release, Seastones was re-mixed and re-mastered in stereo. It includes most of the original 1970–1974 studio forms, those parts of Lagin's concurrent but unfinished composition L that are shared with Seastones, as well as some of the moment forms generated and incorporated into the composition from live performances that took place from 1973 to 1975. This two CD album contains 83 tracks (54 tracks on CD One and 29 tracks on CD Two) and altogether is 111 minutes long.
=== Bjerknes feedback === The close relationship between ocean temperatures and the strength of the trade winds was first identified by Jacob Bjerknes in 1969. Bjerknes also hypothesized that ENSO was a positive feedback system where the associated changes in one component of the climate system (the ocean or atmosphere) tend to reinforce changes in the other. This process is known as Bjerknes feedback. For example, during the growth of El Niño, the reduced contrast in ocean temperatures across the Pacific results in weaker trade winds, further reinforcing the El Niño state. Although these associated changes in the ocean and atmosphere often occur together, the state of the atmosphere may resemble a different ENSO phase than the state of the ocean or vice versa. Because their states are closely linked, the variations of ENSO may arise from changes in both the ocean and atmosphere and not necessarily from an initial change of exclusively one or the other. Conceptual models explaining how ENSO operates generally accept the Bjerknes feedback hypothesis. However, ENSO would perpetually remain in one phase if Bjerknes feedback were the only process occurring. Several theories have been proposed to explain how ENSO can change from one state to the next despite the positive feedback. These explanations broadly fall under two categories. In one view, the Bjerknes feedback naturally triggers negative feedbacks that end and reverse the abnormal state of the tropical Pacific.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.